Clinical Trial Update: Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the bioavailability of subcutaneously administered tislelizumab for first-line treatment of advanced or metastatic non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING